Company Analysis
Sign in

Aligos Therapeutics, Inc. (ALGS)

Nasdaq: ALGS · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade3.9
◀ Past 2.6● Present 4.1▶ Future 4.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

34 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Aligos Therapeutics, Inc.’s names, not what it holds today.

Patents granted
34
34 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 9 in 2024 and 13 in 2023
Applications published
66
8 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry18
Pharmaceuticals16
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Aligos Therapeutics, Inc. its own name
US, as the owner printed on each patent
34 granted
20 published
Aligos Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
46 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 28, 202512,454,691Modified short interfering nucleic acid (siNA) molecules and uses thereofOrganic fine chemistryAligos Therapeutics, Inc.
Sep 30, 202512,428,427Methods and compositions for targeting PD-L1Organic fine chemistryAligos Therapeutics, Inc.
Aug 12, 202512,384,779Bicyclic compoundsOrganic fine chemistryAligos Therapeutics, Inc.
Mar 18, 202512,252,481Anti-viral compoundsOrganic fine chemistryAligos Therapeutics, Inc.
Dec 31, 202412,180,192Modulators of THR-β and methods of use thereofOrganic fine chemistryAligos Therapeutics, Inc.
Oct 29, 202412,129,469Modified short interfering nucleic acid (siNA) molecules and uses thereofPharmaceuticalsAligos Therapeutics, Inc.
Aug 20, 202412,065,428Anti-viral compoundsOrganic fine chemistryAligos Therapeutics, Inc.
Jun 25, 202412,018,015Methods and compositions for targeting PD-L1Organic fine chemistryAligos Therapeutics, Inc.
Apr 16, 202411,957,683Bicyclic compoundsPharmaceuticalsAligos Therapeutics, Inc.
Apr 9, 202411,952,374Bicyclic compoundsPharmaceuticalsAligos Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382618METHODS AND COMPOSITIONS FOR INHIBITING VIRUSPharmaceuticalsAligos Therapeutics, Inc.
Dec 4, 20252025/0368996MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUSBiotechnologyAligos Therapeutics, Inc.
Nov 6, 20252025/0340541METHODS OF PREPARING MODULATORS OF THR-BETAOrganic fine chemistryAligos Therapeutics, Inc.
Oct 2, 20252025/0304561MODULATORS OF THR-BETA AND METHODS OF USE THEREOFOrganic fine chemistryAligos Therapeutics, Inc.
Jul 31, 20252025/0243491PNPLA3-TARGETING SHORT INTERFERING RNA (SIRNA) MOLECULES AND USES THEREOFPharmaceuticalsAligos Therapeutics, Inc.
Jul 31, 20252025/0243187ANTI-VIRAL COMPOUNDSPharmaceuticalsAligos Therapeutics, Inc.
Jun 26, 20252025/0206725MODULATORS OF THR-BETA AND METHODS OF USE THEREOFPharmaceuticalsAligos Therapeutics, Inc.
Jan 9, 20252025/0011789Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses ThereofPharmaceuticalsAligos Therapeutics, Inc.
Nov 14, 20242024/0376078METHODS AND COMPOSITIONS FOR TARGETING PD-L1Organic fine chemistryAligos Therapeutics, Inc.
Nov 7, 20242024/0368128PYRIDAZINONE AND METHODS OF USE THEREOFPharmaceuticalsAligos Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Organic fine chemistry 6 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ALGS · research, not advice